Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 224,979,039 papers from all fields of science
Search
Sign In
Create Free Account
Lisdexamfetamine
A prodrug of the d-isomer of amphetamine, a non-catecholamine sympathomimetic amine with central nervous system (CNS) stimulating activity. Upon…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
Narrower (3)
NRP104
Vyvanse
lisdexamfetamine dimesylate
lisdexamfetamine dimesylate 30 MG Oral Capsule [Vyvanse]
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
The effects of the prodrug Vyvanse on spatial working memory and adiposity in rats
E. Ekstrand
,
H. M. Murphy
,
Cyrilla H. Wideman
Pharmacology, Biochemistry and Behavior
2019
Corpus ID: 201646018
2019
2019
Assessment of comorbidity and social anxiety in adolescents with attention deficit hyperactivity disorder: The SELFIE study
María Jesús Mardomingo Sanz
,
Carlos Sancho Mateo
,
Begoña Soler López
,
en representación del grupo de investigación del estu Selfie
,
Anexo . Grupo de estudio Selfie
Anales de Pediatría (English Edition)
2019
Corpus ID: 53713037
Review
2015
Review
2015
Cognition as a target in major depression: New developments
B. Solé
,
E. Jiménez
,
A. Martínez-Àran
,
E. Vieta
European Neuropsychopharmacology
2015
Corpus ID: 19403086
2015
2015
Comparison of lisdexamfetamine and dextroamphetamine exposures reported to U.S. poison centers
M. Kaland
,
W. Klein‐Schwartz
Clinical toxicology
2015
Corpus ID: 25086724
Abstract Context. Lisdexamfetamine is a pro-drug stimulant that requires the enzymatic hydrolysis of lysine from dexamphetamine…
Expand
Review
2015
Review
2015
Comparative efficacy, acceptability, and tolerability of lisdexamfetamine in child and adolescent ADHD: a meta-analysis of randomized, controlled trials
B. Maneeton
,
N. Maneeton
,
+4 authors
P. Woottiluk
Drug Design, Development and Therapy
2015
Corpus ID: 3136331
Background Several studies have shown that lisdexamfetamine (LDX) is efficacious in children and adolescents with attention…
Expand
Review
2015
Review
2015
Pharmacotherapy of Binge-Eating Disorder: A Review
A. Goracci
,
Silvia di Volo
,
F. Casamassima
,
S. Bolognesi
,
Jim Benbow
,
A. Fagiolini
Journal of addiction medicine
2015
Corpus ID: 43036638
Objectives:The purpose of this article is to provide a comprehensive review of pharmacotherapy for binge eating disorder…
Expand
Review
2014
Review
2014
Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD
N. Maneeton
,
B. Maneeton
,
S. Suttajit
,
J. Reungyos
,
M. Srisurapanont
,
S. Martin
Drug Design, Development and Therapy
2014
Corpus ID: 1625917
Background Recent studies have promised that lisdexamfetamine (LDX) is effective in the treatment of adults with attention…
Expand
2014
2014
Clinical Effects of Lisdexamfetamine and Mixed Amphetamine Salts Immediate Release in Adult ADHD: Results of a Crossover Design Clinical Trial
L. Adler
,
Samuel Alperin
,
Terry L. Leon
,
S. Faraone
Postgraduate medicine
2014
Corpus ID: 37114515
Abstract Objectives: To examine the clinical effects of equivalent doses of single-blind (SB; patient-blind) lisdexamfetamine…
Expand
2013
2013
Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications
J. Setyawan
,
A. Guerin
,
+4 authors
M. Haim Erder
Journal of Medical Economics
2013
Corpus ID: 45904524
Abstract Objective: To compare treatment persistence in attention-deficit/hyperactivity disorder (ADHD) of patients initiated on…
Expand
Review
2010
Review
2010
Use of Psychostimulants in Patients with Dementia
Christian R. Dolder
,
Lauren Nicole Davis
,
Jonathan Mckinsey
The Annals of Pharmacotherapy
2010
Corpus ID: 21792589
Objective: To review the efficacy and safety of psychostimulants for negative behavioral symptoms (ie, apathy, excessive daytime…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE